Preliminary results from a phase 2 trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations

This article has no abstract
Epistemonikos ID: 9287743ddb2409c00a4a76e7a197ef79210b41c8
First added on: Feb 14, 2025